United Therapeutics Corporation Interest Expense Nonoperating
United Therapeutics Corporation (UTHR) reported Interest Expense Nonoperating of $2.90 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Interest Expense
us-gaap:InterestExpenseNonoperating · last filed 2026-08-05
- United Therapeutics Corporation interest expense nonoperating for the quarter ending 2026-06-30 was $2.90M, a 60.27% decline year-over-year.
- United Therapeutics Corporation interest expense nonoperating for the quarter ending 2026-03-31 was $3.00M, a 50.82% decline year-over-year.
- United Therapeutics Corporation interest expense nonoperating for the quarter ending 2025-12-31 was $3.10M, a 60.76% decline year-over-year.
- United Therapeutics Corporation interest expense nonoperating for the quarter ending 2025-09-30 was $3.00M, a 70.30% decline year-over-year.
- United Therapeutics Corporation interest expense nonoperating for fiscal 2025 was $19.50M, a 54.55% decline from fiscal 2024.
- United Therapeutics Corporation interest expense nonoperating for fiscal 2024 was $42.90M, a 27.66% decline from fiscal 2023.
- United Therapeutics Corporation interest expense nonoperating for fiscal 2023 was $59.30M, a 83.02% increase from fiscal 2022.
- United Therapeutics Corporation interest expense nonoperating for fiscal 2022 was $32.40M.
| Period end | Interest Expense Nonoperating 3 month | Interest Expense Nonoperating 6 month | Interest Expense Nonoperating 9 month | Interest Expense Nonoperating 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.90M 10-Q · filed 2026-08-05 | $5.90M 10-Q · filed 2026-08-05 | $9.00M derived: sum of 3 quarters · filed 2026-08-05 | $12.00M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $3.00M 10-Q · filed 2026-05-06 | $6.10M derived: sum of 2 quarters · filed 2026-05-06 | $9.10M derived: sum of 3 quarters · filed 2026-05-06 | $16.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $3.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $6.10M derived: sum of 2 quarters · filed 2026-02-25 | $13.40M derived: sum of 3 quarters · filed 2026-08-05 | $19.50M 10-K · filed 2026-02-25 |
| 2025-09-30 | $3.00M 10-Q · filed 2025-10-29 | $10.30M derived: sum of 2 quarters · filed 2026-08-05 | $16.40M 10-Q · filed 2025-10-29 | $24.30M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $7.30M 10-Q · filed 2026-08-05 | $13.40M 10-Q · filed 2026-08-05 | $21.30M derived: sum of 3 quarters · filed 2026-08-05 | $31.40M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $6.10M 10-Q · filed 2026-05-06 | $14.00M derived: sum of 2 quarters · filed 2026-05-06 | $24.10M derived: sum of 3 quarters · filed 2026-05-06 | $35.70M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $7.90M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $18.00M derived: sum of 2 quarters · filed 2026-02-25 | $29.60M derived: sum of 3 quarters · filed 2026-02-25 | $42.90M 10-K · filed 2026-02-25 |
| 2024-09-30 | $10.10M 10-Q · filed 2025-10-29 | $21.70M derived: sum of 2 quarters · filed 2025-10-29 | $35.00M 10-Q · filed 2025-10-29 | $50.10M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $11.60M 10-Q · filed 2025-07-30 | $24.90M 10-Q · filed 2025-07-30 | $40.00M derived: sum of 3 quarters · filed 2026-02-25 | $55.60M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $13.30M 10-Q · filed 2025-04-30 | $28.40M derived: sum of 2 quarters · filed 2026-02-25 | $44.00M derived: sum of 3 quarters · filed 2026-02-25 | $58.80M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $15.10M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $30.70M derived: sum of 2 quarters · filed 2026-02-25 | $45.50M derived: sum of 3 quarters · filed 2026-02-25 | $59.30M 10-K · filed 2026-02-25 |
| 2023-09-30 | $15.60M 10-Q · filed 2024-10-30 | $30.40M derived: sum of 2 quarters · filed 2024-10-30 | $44.20M 10-Q · filed 2024-10-30 | |
| 2023-06-30 | $14.80M 10-Q · filed 2024-07-31 | $28.60M 10-Q · filed 2024-07-31 | ||
| 2022-12-31 | $32.40M 10-K · filed 2025-02-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |